Biotech & Pharma

On Its 15th Anniversary, Foresite Capital Looks Ahead

23 sec read9 views0 listens

Foresite Capital forecasts growth in biopharma VC financings and IPOs starting 2026, supported by increased investment volumes despite fewer deals in recent years. The firm highlights its success in incubating startups like Alumis and Xaira Therapeutics, emphasizing the importance of leveraging global innovation sources, particularly from China, to drive therapeutic advancements.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Startups & VC18 hours ago23 sec read

Craft's Ilya Levtov Never Learned To Code. He Built A Software Company Anyway.

Ilya Levtov, a non-technical founder of Craft, a supply chain software company, highlights the challenges and advantages of building a tech startup without coding skills. Despite lacking technical expertise, Levtov successfully raised $42 million and...

Ali Nemati

Tech & Gadgets19 hours ago27 sec read

Timia Capital expands B2B tech lending capacity with funding from SAF Group

Timia Capital, a Toronto-based lender specializing in debt financing for B2B technology companies, has expanded its lending capacity by $60 million CAD through a new credit facility from SAF Group. This expansion enables Timia to provide larger loans...

Ali Nemati

Startups & VC20 hours ago30 sec read

Fintech funding in Singapore drops to US$499M as dealmaking becomes more selective

Fintech funding in Singapore has significantly declined in the first half of 2026, raising just over US$499 million across 53 deals, a sharp drop from the previous year. Investors are now highly selective, focusing capital on mature, defensible platf...

Ali Nemati